Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2890-2026

Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic Recall

Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic

FDA recall Class II

Ongoing

FDA lists this Class II recall for Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2890-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jul 6, 2026
FDA report date
Aug 12, 2026
Quantity in commerce
7018 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic

Affected model & UDI checker

Search the exact identifiers published for Z-2890-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
11537225Atellica CH Urine Albumin REF: 11537225, in vitro diagnosticCheck source noticeNot specified
Not specifiedAtellica CH Urine Albumin REF: 11537225, in vitro diagnosticCheck source notice00630414611099
FDA code information

All Lots within expiry/UDI: 00630414611099

View the original FDA recall notice

Why was this product recalled?

Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

What actions did Siemens Healthcare Diagnostics, Inc. take?

On July 6, 2026, Siemens Healthineers issued a Urgent Medical Device Recall to affected consignees via Fed Ex. Siemens Healthineers ask consignees to take the following actions: 1. Discontinue Atellica CH Urine Albumin (UAlb) testing and transition to the Atellica CH Microalbumin_2 (ALB_2) reagent, SMN 11097610, and Atellica CH Microalbumin_2 Calibrator (ALB_2 CAL), SMN 11099435, as an alternate test solution. 2. Replace all reaction cuvette segments following discontinuation of UAlb testing. Refer to the Atellica Solution Online Help for instructions on replacing reaction cuvette segments. 3. Complete the Field Correction Effectiveness Check Form attached to this letter and return within 30 days. 4.Credit will be issued for unexpired UAlb reagent (SMN 11537225), UAlb calibrator (SMN 11537247), and reaction cuvettes segments, as applicable. 5. Please review this letter with your Medical Director to determine the appropriate course of action, including whether review of any previously generated results is warranted. 6. Please retain this letter with your laboratory records and forward this letter to those who may have received the affected product.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology